Publications
Detailed Information
SGLT-2 inhibitors and GLP-1 receptor agonists in metabolic dysfunction-associated fatty liver disease
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Moon, Jun Sung | - |
dc.contributor.author | Hong, Jun Hwa | - |
dc.contributor.author | Jung, Yong Jin | - |
dc.contributor.author | Ferrannini, Ele | - |
dc.contributor.author | Nauck, Michael A. | - |
dc.contributor.author | Lim, Soo | - |
dc.date.accessioned | 2022-09-29T03:18:29Z | - |
dc.date.available | 2022-09-29T03:18:29Z | - |
dc.date.created | 2022-06-16 | - |
dc.date.issued | 2022-06 | - |
dc.identifier.citation | Trends in Endocrinology and Metabolism, Vol.33 No.6, pp.424-442 | - |
dc.identifier.issn | 1043-2760 | - |
dc.identifier.uri | https://hdl.handle.net/10371/184649 | - |
dc.description.abstract | © 2022 Elsevier LtdMetabolic dysfunction-associated fatty liver disease (MAFLD) is a chronic condition that affects nearly one billion people globally, characterized by triacylglycerol accumulation in the liver as a consequence of metabolic abnormalities (obesity and impaired glucose regulation). Low-grade inflammation, oxidative stress, mitochondrial dysfunction, and dysbiosis in gut microbiota are involved in the etiology of MAFLD, and both cardiovascular events and hepatic complications are the long-term consequences. In the absence of approved therapies for this condition, sodium–glucose cotransporter 2 inhibitors (SGLT-2 Is) and glucagon-like peptide 1 receptor agonists (GLP-1 RAs) have the specific advantage of lowering body weight and providing cardiovascular benefits. Here, we discuss potential roles for SGLT-2 Is and GLP-1 RAs in the prevention and treatment of intrahepatic triacylglycerol accumulation and associated inflammation and/or fibrosis. | - |
dc.language | 영어 | - |
dc.publisher | Elsevier BV | - |
dc.title | SGLT-2 inhibitors and GLP-1 receptor agonists in metabolic dysfunction-associated fatty liver disease | - |
dc.type | Article | - |
dc.identifier.doi | 10.1016/j.tem.2022.03.005 | - |
dc.citation.journaltitle | Trends in Endocrinology and Metabolism | - |
dc.identifier.wosid | 000800447500006 | - |
dc.identifier.scopusid | 2-s2.0-85129636553 | - |
dc.citation.endpage | 442 | - |
dc.citation.number | 6 | - |
dc.citation.startpage | 424 | - |
dc.citation.volume | 33 | - |
dc.description.isOpenAccess | N | - |
dc.contributor.affiliatedAuthor | Lim, Soo | - |
dc.type.docType | Review | - |
dc.description.journalClass | 1 | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.